Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC9H7ClN2 |
InChIKeyNDRZSRWMMUGOBP-UHFFFAOYSA-N |
CAS Registry1198-40-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 29 Dec 2023 |